Yung-Hsi Wen
Interventional Cardiology · Glendale, CANPI 1366585309
Payments from drug & device makers
Across 183 payments — averaging $16.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$582
- Novartis$525
- Johnson & Johnson$376
- Amarin Pharma, Inc.$246
- AstraZeneca$239
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$232
- plus $905 from 13 others
What the payments were for
- Food & beverage$3,08099%
- Education$241%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 42 | $582 |
| Novartis | 32 | $525 |
| Johnson & Johnson | 14 | $376 |
| Amarin Pharma, Inc. | 12 | $246 |
| AstraZeneca(2 entities) | 13 | $239 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $232 |
| Esperion Therapeutics, Inc. | 22 | $174 |
| E.r. Squibb & Sons, L.L.C. | 11 | $161 |
| Boehringer Ingelheim | 5 | $123 |
| Medtronic | 1 | $100 |
| Pfizer | 4 | $78 |
| Merck | 4 | $74 |
| Kowa Pharmaceuticals America, Inc. | 2 | $45 |
| Sanofi-aventis U.S. LLC | 2 | $39 |
| Tactile Systems Technology Inc | 2 | $31 |
| Portola Pharmaceuticals, LLC | 1 | $26 |
| Novo Nordisk | 1 | $22 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| W. L. Gore & Associates, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CoreValve Evolut$100
How this compares
$3,104 in reported general payments places this provider in the 25th percentile of 585 interventional cardiology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rosuvastatin Calcium | 11 | $163 |
| Ezetimibe | 12 | $132 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Glendale
- Rajendra MakkarWest Hollywood$16.6M
- Fahed BitarCovina$9.9M
- Rahul SharmaStanford$6.6M
- Matthew Pricela Jolla$5.8M
- David LeeStanford$5.7M
- Saibal KarThousand Oaks$5.4M
- Mehrdad ArianiNorthridge$5M
- Frederick St GoarMountain View$4.2M
- Sammy ElmariahSan Francisco$4.2M
- William FearonStanford$3.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.